The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study
- 308 Downloads
The objective of the study was to assess the natalizumab effect on the course of cognitive impairment in patients with relapsing-remitting multiple sclerosis (MS). Patients with active relapsing-remitting MS (n = 17) were treated with natalizumab for 1 year. The quasi control group included patients (n = 7) with clinically stable MS. Assessment of disease course [expanded disability status scale (EDSS); number of relapses] and neuropsychological impairment [Wisconsin card sorting test (WCST); controlled oral word associations; verbal/non-verbal memory tests; paced auditory serial addition test] was conducted at baseline and after 1 year. Natalizumab-treated patients experienced significantly fewer relapses compared with the previous year (P < 0.05). At 1-year follow-up, EDSS score was unchanged and neuropsychological assessments of memory/executive functions showed a significant improvement in natalizumab-treated patients (all P < 0.05). No changes were observed in the quasi control group. This preliminary study suggests that natalizumab could be effective in ameliorating cognitive functions in patients with active relapsing-remitting MS, over 1-year follow-up.
KeywordsMultiple sclerosis Natalizumab Cognitive function Relapsing-remitting
The authors thank Wolters Kluwer (Auckland, New Zealand), who provided medical writing support funded by Biogen Idec.
- 1.IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661Google Scholar
- 2.Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276PubMedGoogle Scholar
- 6.Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260CrossRefPubMedGoogle Scholar
- 10.Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B et al (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15:779–788CrossRefPubMedGoogle Scholar
- 18.Novelli G, Papagno C, Capitani E, Laiacona N, Vallar G, Cappa SF (1986) Tre test clinici di ricerca e produzione lessicale.Taratura su soggetti normali. Arch Psicol Neurol Psichiatr 47:477–506Google Scholar
- 19.Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 8(Suppl):1–120Google Scholar
- 20.Rao SM, Cognitive Function Study Group N (1990) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. National Multiple Sclerosis Society, New YorkGoogle Scholar
- 21.Meyers J, Meyers K (1995) Rey complex figure and recognition trial: professional manual. Psychological Assessment Resources, OdessaGoogle Scholar
- 24.Patti F, Amato MP, Tola MR, Trojano M, Ferrazza P, Bastianello S (2008) Effects of subcutaneous interferon beta on disease parameters and cognition in patients with early relapsing-remitting multiple sclerosis: longitudinal clinical and cognitive result from the COGIMUS (Cognitive Impairment in Multiple Sclerosis) study. Neurology 70:A87Google Scholar